Agenus’ botensilimab/balstilimab combination achieves unprecedented survival in advanced colorectal cancer

In a post by Agenus on Linkedin, it says, “ESMO Late-Breaking GI Data: Agenus’ botensilimab/balstilimab combination achieves unprecedented survival in advanced colorectal cancer.
Median overall survival of 20.9 months for patients without active liver metastases surpasses the recently reported 12.9-month benchmark with standard of care in this population.”

For details: Click here

Source: Agenus/Linkedin